Bucindolol
| |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard |
100.114.291 |
Chemical and physical data | |
Formula | C22H25N3O2 |
Molar mass | 363.45 g/mol |
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]
See also
References
- 1 2 "formularyjournal.modernmedicine.com".
- ↑ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
- ↑ "FDA rejects bucindolol and questions trial integrity « CardioBrief".
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.